

UMass Chan Medical School

eScholarship@UMassChan

Open Access Publications by UMMS Authors

2019-02-27

Management of microscopic colitis: challenges and solutions

Julia Shor

University of Massachusetts Medical School

Et al.

Let us know how access to this document benefits you.

Follow this and additional works at: <https://escholarship.umassmed.edu/oapubs>

 Part of the [Digestive System Diseases Commons](#), [Gastroenterology Commons](#), and the [Therapeutics Commons](#)

Repository Citation

Shor J, Churrango G, Hosseini N, Marshall C. (2019). Management of microscopic colitis: challenges and solutions. Open Access Publications by UMMS Authors. <https://doi.org/10.2147/CEG.S165047>. Retrieved from <https://escholarship.umassmed.edu/oapubs/3771>

Creative Commons License



This work is licensed under a [Creative Commons Attribution-NonCommercial 3.0 License](#)

This material is brought to you by eScholarship@UMassChan. It has been accepted for inclusion in Open Access Publications by UMMS Authors by an authorized administrator of eScholarship@UMassChan. For more information, please contact Lisa.Palmer@umassmed.edu.

Management of microscopic colitis: challenges and solutions

Julia Shor¹
Gustavo Churrango¹
Nooshin Hosseini²
Christopher Marshall¹

¹Department of Gastroenterology,
University of Massachusetts Medical
School, Worcester, MA, USA;

²Department of Gastroenterology,
Mount Sinai Hospital, New York, NY,
USA

Abstract: Microscopic colitis (MC) is a chronic inflammatory bowel disease characterized by nonbloody diarrhea in the setting of normal appearing colonic mucosa. MC has two main subtypes based on histopathologic features, collagenous colitis and lymphocytic colitis. Management of both subtypes is the same, with treatment goal of reducing the number of bowel movements and improving consistency. First-line treatment involves counseling the patient about decreasing their risk factors, like discontinuing smoking and avoiding medications with suspected association such as NSAIDs, proton pump inhibitor, ranitidine, and sertraline. Starting loperamide for immediate symptomatic relief is used as an adjunct to therapy with glucocorticoids. Budesonide is considered first-line treatment for MC given its favorable side effect profile and good efficacy, though relapse rates are high. Systemic glucocorticoids should be reserved to patients unable to take budesonide. In glucocorticoid refractory disease, medications that have been tried include cholestyramine, bismuth salicylate, antibiotics, probiotics, aminosalicylates, immunomodulators, and anti-tumor necrosis factor-alpha inhibitors. More research is needed for the creation of a systematic stepwise approach for relapsing and refractory disease.

Keywords: microscopic colitis, diarrhea, collagenous colitis, lymphocytic colitis, management, inflammatory colitis

Introduction

Microscopic colitis (MC) is a chronic inflammatory bowel disease characterized by nonbloody diarrhea in the setting of normal appearing colonic mucosa and distinct histopathologic features. It has a preponderance for middle-aged women and is associated with various autoimmune disorders, as well as widely used medications including NSAIDs.¹ MC has two main subtypes, collagenous colitis (CC) and lymphocytic colitis (LC), as well as an incomplete variant. Although MC has been well-described in the medical literature since the 1970s, many aspects of this disease remain poorly understood and few high-quality studies are available to guide therapy. There have been promising advancements in the understanding of MC, as several international medical societies have published recent statements and guidelines on the diagnosis and treatment of MC, and various studies are on the horizon exploring new therapies such as novel biologics and even fecal transplant.^{2,3}

General overview Epidemiology

Based on a recent meta-analysis, the annual overall incidence of CC is 4.14 per 100,000 person-years and 4.85 per 100,000 person-years for LC. The overall prevalence of CC

Correspondence: Julia Shor
Department of Gastroenterology,
University of Massachusetts Medical
School, 55 N Lake Ave, Worcester, MA
01605, USA
Email julia.shor@umassmemorial.org

is 49.21 cases per 100,000 person-years and 63.05 cases per 100,000 person-years for LC.⁴ It is important to note that most of the data about the incidence and prevalence of MC are from the developed Western world, namely the USA, Canada, Spain, the Netherlands, and Denmark. Data from the developing world are lacking. Age increases the risk of MC with an OR of 8.3 for age >65 years compared with <65 years.^{5,6} The incidence is higher in women than in men, with a female-to-male incidence ratio of 3.05 for CC and 1.92 for LC.⁴

Risk factors

While the etiology of MC is still unknown, various independent risk factors, broadly including medications, tobacco, and autoimmune conditions, have been identified, which are implicated in both developing and flaring of MC. The widely used medications include proton pump inhibitors, NSAIDs, beta-blockers, statins, and selective serotonin reuptake inhibitors.⁷ In fact, a recent Danish case-control study of 10,652 patients found a strong association of proton pump inhibitors with both CC (OR 6.98) and LC (OR 3.95), with the strongest association being with the current use of lansoprazole.⁸ In addition to the classically described medications thought to have association with MC, new medications, namely novel chemotherapeutic agents immune checkpoint inhibitors (ICPIs), have been implicated in causing histologically proven MC. It is important to distinguish this entity as patients on ICPIs had a more aggressive course often requiring hospitalization and were treated with more aggressive immunosuppression such as oral and intravenous corticosteroids and infliximab as well as vedolizumab.⁹ While medications are classically thought of as being causative for MC, evidence to this fact remains present only in certain individual cases with larger scale studies unable to replicate the cause and effect relationship.¹⁰ Smoking has also been found to have an association with MC, leading to the onset of disease >10 years earlier than seen in nonsmokers.¹¹ Various autoimmune disorders, including celiac disease, type 1 diabetes, autoimmune thyroiditis, and inflammatory arthritis, are also associated with greater risk of MC.⁷ In fact, patients with celiac disease have a 70-fold risk of developing MC over the general population, thought to be due to association with the human leukocyte antigen-DR3-DQ2, which is prevalent in both MC and celiac disease.^{12,13} Lastly, other lymphocytic disorders of the gastrointestinal tract, such as lymphocytic gastritis, lymphocytic esophagitis, and duodenal intraepithelial lymphocytosis, have also been associated with MC.¹⁴

Pathophysiology

The exact mechanism of diarrhea in MC remains largely unknown but is thought to be multifactorial. Mucosal inflammation has been proposed as the most pathophysiologic mechanism of the diarrhea. This may be due to mucosal changes due to inflammation that lead to reduced sodium and chloride absorption, inhibition of the chloride/bicarbonate exchange channels, and a decrease in passive permeability.¹⁵ These changes consequently lead to a secretory diarrhea. An osmotic element has also been studied and is supported by the finding that periods of fasting decrease fecal weight.¹⁶ Bile salt malabsorption may also play a factor, as bile acid sequestrants have successfully been used to treat diarrhea in MC. In one study, a selenium-labeled homocholic acid taurine test was used to study bile acid malabsorption in patients with CC, and 44% (12/27) were found to have an abnormal test.¹⁷ Mucosal injury from luminal contents has also been proposed as another factor leading to diarrhea. This was evidenced by studying patients who underwent diverting ileostomy, who were found to have histologic improvement of the MC. This improvement later reverted when the ileostomy was reversed.¹⁸ The microbiome has also been implicated in the pathogenesis of MC, with an identified increase in the proinflammatory sulfur-reducing bacterial family Desulfovibrionales and a decrease in Coriobacteriaceae, which is seen in abundance in the healthy gastrointestinal tract.¹⁹ Additionally, given that the disease is most prevalent in postmenopausal women, hormones are thought to play a role in the pathophysiology of MC. In a pooled analysis by the Nurses' Health Study, exogenous oral contraceptive and menopausal hormone therapy use were associated with the increased risk of MC, thereby implicating estrogen in playing a role in inflammation of the gastrointestinal tract.²⁰

Symptoms

The hallmark symptom of MC is chronic, nonbloody, watery diarrhea. The diarrhea can develop suddenly, or develop progressively, to a frequency reported up to 15 times a day. The watery diarrhea is often associated with abdominal pain, urgency, incontinence, nocturnal symptoms, and/or weight loss.^{6,21} Fatigue has also been noted to be a prevalent symptom in MC, as reported by both Nyhlin et al and Kane et al.^{22,23} Fatigue severity was associated with concurrent anxiety, depression, and somatization in MC.²³ While a recent systematic review and meta-analysis showed that one in three patients with MC can have symptoms of irritable bowel syndrome, namely alterations in bowel habits and abdominal pain, the

rate of symptoms was similar to the general population, despite recent case–control studies showing the opposite.²⁴ Given overlap with various other gastrointestinal illnesses, the diagnosis can often be difficult to pinpoint and as such, the differential diagnosis for MC is broad, including irritable bowel syndrome with diarrhea, medication-induced diarrhea, inflammatory bowel disease, and an array of malabsorptive disorders.

Diagnosis

Once MC is suspected, the patient is sent for endoscopic evaluation with biopsies, and the diagnosis is ultimately made via characteristic histologic findings. While there can be laboratory abnormalities that can occur in up to 50% of patients with MC, including elevated erythrocyte sedimentation rate and autoantibodies such as antinuclear antibody, rheumatoid factor, antimitochondrial antibody, antineutrophilic cytoplasmic antibodies, anti-*Saccharomyces cerevisiae* antibodies, and antithyroid peroxidase antibodies, these are neither sensitive nor specific to the disease and are not necessary for diagnosis.^{6,25} Similar to laboratory evaluation, fecal biomarkers such as calprotectin and lactoferrin are of little utility for diagnosing MC. While calprotectin levels were found to be increased in active vs quiescent disease, 38% of patients in the study with active MC had negative calprotectin levels.²⁶ Fecal lactoferrin fared worse, with only 3 of 39 patients evaluated having a positive test result in one study, and 1 of 21 patients in another.^{26,27} Colonoscopy usually reveals normal colonic mucosa on endoscopic examination. The American Society of Gastrointestinal Endoscopy recommends two or more biopsies of the transverse, sigmoid, and descending colon if flexible sigmoidoscopy is performed and two of more biopsies of the right, transverse, descending, and sigmoid colon if colonoscopy is performed.²⁸ We recommend that colonoscopy, rather than flexible sigmoidoscopy, be routinely performed if MC is suspected as histologic changes can be patchy in distribution, and inflammatory severity is greatest in the more proximal colon. Flexible sigmoidoscopy, however, can diagnose >90% of MC.^{29,30} Classic histologic features of LC include >20 intraepithelial lymphocytes per 100 epithelial cells. Histologic features of CC include a 10–20 μm diameter of thickened subepithelial collagen band, detachment of surface epithelial cells from subepithelial collagen, and an increase in intraepithelial lymphocytes however not to the same extent as of LC and not essential to histologic diagnosis.³¹ The histology of incomplete MC, which seeks to widen the catchment of symptomatic patients who may not classically fit into the diagnostic criteria above, includes

>10 and <20 intraepithelial lymphocytes for iLC and >5 and <10 μm thickness of the collagen band for iCC.³²

Prognosis

While the diagnosis of MC does not alter mortality or longevity, it certainly impacts the quality of life. A Spanish study evaluating the natural history of MC with a median follow-up time of 8 years showed that 75% of patients achieved remission free from drugs for more than a year. However, while 93% of patients who achieved remission spontaneously went on to have sustained remission, only 60.5% of patients who achieved drug-induced remission remained disease free after a year.³³ Additionally, despite being in clinical remission, patients can often have lasting symptoms including abdominal pain, fatigue, arthralgia, or myalgia, several years after diagnosis compared with controls.²² While MC can have a lasting impact on the health-related quality of life (HRQOL) of patients, it is important to note that it is not associated with an increased risk of colorectal cancer. In fact, patients with MC had a negative association with neoplastic polyps compared with patients who had chronic diarrhea without MC, with an OR =0.22.³⁴

Management

The overall goal in the management of MC is symptomatic improvement, the exact definition of which varies greatly between studies. A large population-based study has defined clinical remission as improvement in bowel movements to less than three per day or less than one watery stool daily over the course of 1 week.^{1,2,35} This has been shown to correlate significantly with an increase in HRQOL and consequently has been widely utilized. It is yet unclear whether histologic remission should be a goal that drives therapy.^{36,37} Given that, to date, no biomarker has been identified to assess the severity of disease, defining disease activity by clinical variables is crucial. The Microscopic Colitis Disease Activity Index was developed recently to help further define management goals. It is the first prospective study to identify disease activity and to name six variables (unformed stools, nocturnal stools, abdominal pain, weight loss, fecal urgency, and fecal incontinence), which they showed to correlate significantly with quality of life. The study, which included 162 patients, hopes to standardize guidelines for remission and offer a more direct comparison of available therapies.^{21,38} Lastly, there is currently discussion regarding including histologic remission as a potential end point of therapy.³⁹

We have provided an algorithmic approach to the therapeutic management of MC below (Figure 1).




Figure 1 Therapeutic management algorithm for microscopic colitis.

Lifestyle modifications and symptom management

MC has very clearly defined risk factors, including smoking and various medications. Lifestyle modifications including decreasing caffeine, dairy (in patients with lactose intolerance), and alcohol consumption may improve the diarrhea seen in MC.³⁹ It is also critical that concomitant celiac disease

and bile acid malabsorption be appropriately diagnosed and managed, as they can be associated with MC.⁴⁰

Withdrawal of medications that have been implicated in causing MC may be considered as an addition to the standard first-line therapy. The medications with the strongest known association are acarbose, aspirin, NSAIDs, proton pump inhibitors (lansoprazole and omeprazole), ranitidine,

sertraline, and ticlopidine.^{39,41} In a true case of a drug-induced MC, clinical and histologic improvement as well as recurrence with rechallenge should be documented.⁴²

Loperamide was until recently the only identified therapy for MC. It continues to have a role in symptomatic management with doses of 2–16 mg/day according to retrospective studies.⁴⁰ It is important to note that clinical remission is seldom achieved in loperamide monotherapy, and there is no evidence of histologic improvement.³⁷ No randomized placebo-controlled trials have been done to study the use of loperamide in MC.

Budesonide

Budesonide is an oral corticosteroid with very low systemic bioavailability. This is achieved via the capsule, which is formulated to dissolve in a pH-dependent manner to deliver the drug into the ileum and ascending colon.⁴³ The 2016 AGA clinical guideline for the management of MC recommends that budesonide be used as first-line therapy.³ This is based on six randomized clinical trials showing clinical response and five showing histological response.^{44–49} This was further augmented by a favorable side effect profile as well as the ease of once daily dosing, though cost was noted as a barrier to therapy.

A recent 2017 Cochrane review echoed these sentiments and demonstrated that budesonide 9 mg/day for 6–8 weeks was effective in inducing both clinical and histologic remission. In two examined studies with a total of 57 patients, 88% showed clinical response to budesonide as opposed to 38% to placebo and 78% showed histologic response compared with 33% with placebo.⁵⁰ The “number needed to treat” was two for CC and three for LC. Notably, the median time to remission was ~10.5 days.⁵¹ A recent randomized, placebo-controlled, multicenter study showed that budesonide 9 mg daily induced clinical remission at 8 weeks in 79% of patients vs 42% with placebo. Histologic remission was attained in 68% of budesonide group vs 21% of placebo group.⁵² Further randomized controlled trials have shown that remission can be maintained for 6 months, with doses as low as 6 mg/day.^{42,51} Skin hematoma, cataracts, and increased blood glucose levels have been reported as side effects of budesonide therapy.⁴²

Despite the effectiveness of budesonide, relapse rates have been reported at 40%–81% and can occur as soon as 2 weeks after cessation of therapy.⁵³ Certain factors, such as longer duration of symptoms prior to initiation of therapy, age over 60 years, and more severe baseline diarrhea, can be foreboding.^{1,41,51,53} A prospective, randomized, placebo-controlled study by Münch et al aimed to tackle the high relapse rate by

examining low-dose (4.5 mg/day) budesonide maintenance therapy for 12 months. Remission was maintained at 1 year in 61.4% of patients in the budesonide arm vs 16.7% in the placebo arm. There were no serious adverse events reported with more long-term therapy in this study, and overall side effects were reported in 7 out of 44 patients.⁵¹ In another study by Fernandez-Bañares, 53% of patients had at least one clinical relapse after initial withdrawal of budesonide and were either resumed on 9 mg/day and tapered to the lowest effective dose or resumed at the previous lowest effective dose. Twenty-one percent of patients needed a budesonide dose >6 mg daily to maintain clinical remission, and the others tolerated 3 mg/day or 3 mg every other day for maintenance of remission. The authors did note that in long-term use of >6 mg budesonide daily, consideration for alternative therapies such as thiopurines could be considered.⁵⁴

On the horizon are new studies on the use of beclomethasone dipropionate, a synthetic corticosteroid with topical colonic release. In an open-label multicenter study of 23 patients, patients were given beclomethasone 10 mg/day for 4 weeks, followed by 5 mg/day for 4 weeks. Their symptoms were assessed via the Bristol stool scale and a telephone interview. Remission was defined as less than eleven loose stools over 7 days. At week 8, 70% of patients were in remission.⁵⁵ While beclomethasone does appear to induce remission, a 2010 trial demonstrated that only 26% of patients (from the 84% with initial response) maintained clinical remission at 1 year, bringing its longevity into question.⁵⁰ While beclomethasone dipropionate is promising, it is not available in the USA and to date is only in use in Europe.

Systemic corticosteroids

Unlike budesonide, the role of systemic corticosteroids in the treatment of MC is limited. The 2016 AGA guideline recommends treatment with prednisone or prednisolone only when no other treatment is available or when cost is a significant hindrance.³ Most of the evidence for the use of systemic corticosteroids is inferred from the successes of budesonide as well as their long-standing use in medical practice, however, is considerably limited by their side effect profile. One small randomized trial of 12 patients showed a 22% response rate in the prednisone arm vs no response in the three patients in the control arm.⁵⁶ A population-based study in 2013 by Gentile et al found that the response to prednisolone was 52.9% (as compared to 82.5 with budesonide) and the rate of recurrent disease was higher than with budesonide therapy (HR 0.38, CI 0.18–0.85, $P=0.02$).⁵⁷ A double-blind, placebo-controlled randomized trial of 50 mg/day of prednisolone

for CC showed incomplete remission in two of nine patients treated.⁵⁸ Overall, there is a paucity of evidence for systemic corticosteroids in the treatment of MC, and its effects are marginal compared with budesonide.³⁹

Refractory MC Bismuth salicylate

Bismuth salicylate is recommended by the 2016 AGA guideline as a second-line therapy for MC when budesonide is unable to be used, either due to cost or adverse effects.³ This is based on a small randomized study of 14 patients which showed that all seven of seven patients in the intervention arm (eight to nine 262 mg bismuth tablets divided into three doses per day for 8 weeks) had clinical response vs none of the patients in the placebo arm.⁵⁹ The study included nine patients with CC and five patients with LC. Additionally, patients treated with bismuth salicylate had a 3-fold, albeit not statistically significant, likelihood of achieving a concomitant histologic response. A retrospective study showed complete response in 53% of patients and partial response in 28% of patients taking three tablets (262 mg each) of bismuth salicylate three times a day.⁶⁰ Therapy was noted to be more effective in patients with milder symptoms and older patients. There has also been a case report of lower dose bismuth subsalicylate, two tablets of 262 mg each, three times daily for 1 month, resulting in clinical and histologic remission.⁶¹ While there have not been any adverse events related to bismuth salicylate treatment and the cost of therapy is relatively low, there is potential for neurotoxicity and nephrotoxicity with long-term use, and the significant pill burden is a conceivable barrier to compliance with therapy.⁶²

Cholestyramine

Cholestyramine is thought to play a role in the treatment of MC due to its bile acid-binding capacity, as bile acid malabsorption has been thought to play a role in pathogenesis of MC; however, it also adheres to bacterial toxins, which have been implicated in the pathophysiology of CC.² In a retrospective study of 27 patients with biopsy-proven CC, the rate of bile acid malabsorption was noted to be 44%, and cholestyramine therapy with 4 g two to three times daily (or colestipol 5 g two to three times daily) resulted in clinical remission in 11/12 (92%) patients with bile acid malabsorption compared with 10/15 (67%) without. Ultimately, 21/27 (78%) patients had improvement with bile acid-binding therapy.¹⁷ Cholestyramine was also studied as an adjunct to mesalamine in a randomized control trial of 41 patients and did not show any added benefit.⁶³ Given the significant

potential for drug–drug interactions and the lack of proven benefit, the AGA recommended against combination therapy with cholestyramine. No randomized clinical trials have been done to elucidate the appropriateness of cholestyramine monotherapy in MC. Retrospective studies, however, have shown response rates of 59%–65%.^{6,64}

Antibiotics and probiotics

AGA recommends against treatment with *Boswellia serrata* as well as other probiotics. While there has been evidence showing some efficacy, including a single randomized controlled trial of 31 patients in which 44% of patients treated with *Boswellia* showed clinical improvement (however, no histologic or quality of life improvement) compared with 27% of patients treated with placebo, the results were not statistically significant.⁶⁵ There is also concern about the lack of standardization between preparations of *B. serrata*.³ Similar concerns apply to the wide variety of probiotics available on the market at present. A randomized placebo-controlled trial of *Lactobacillus acidophilus* LA-5 and *Bifidobacterium animalis* AB-Cap-10 failed to demonstrate a benefit over placebo.⁶⁶ An open-label uncontrolled trial of *Escherichia coli* strain Nissle 1917 did show improvement in stool frequency (64% of patients) and stool consistency (50% of patients).⁶⁷ A randomized open-label trial comparing the probiotic VSL#3 to mesalamine in 30 patients found that 5/11 (46%) patients on VSL#3 compared with 1/13 (8%) patients on mesalamine achieved remission.⁶⁸ While VSL#3 may offer a benefit, randomized placebo-controlled trials would be necessary. No controlled clinical trials evaluating antibiotic use exist; however, metronidazole and erythromycin have been used anecdotally with varying success.¹ In a large retrospective clinical review of 163 patients with CC, the rate of response to antibiotics (metronidazole, erythromycin, and penicillin G) was noted to be 60%, but there was no mention of concomitant treatment, dosing, or relapse rate.⁶ Another large retrospective review of 199 patients with LC found that 23 patients were given metronidazole with 14 showing clinical response (61%), however, six relapsed within 1 month.⁶⁹

Aminosalicylates

Mesalamine can be considered as an alternative to budesonide therapy when the latter is not feasible due to contraindications or poor clinical response, despite varying evidence on its success.³ Two randomized placebo-controlled trials did not show any effect of mesalamine 3 g/day compared with placebo in short-term 8-week induction.^{48,52} As previously mentioned, a comparison between mesalamine and mesalamine plus

cholestyramine was undertaken and showed a high remission rate (85% in LC and 91% in CC) in both treatment arms, with the addition of cholestyramine being slightly superior.⁶³ Efficacy has otherwise been supported solely by observational studies and case series. While the 2016 AGA guideline recommends mesalamine as an alternative, the European guidelines (Spanish microscopic Colitis Group, European Microscopic Colitis Group) do not, as there is a clear need for more research on the matter.^{2,3,37}

Immunomodulators

Immunomodulators such as azathioprine or 6-MP may have a role in the treatment of severe, steroid dependent, or refractory disease. In one small open study, azathioprine induced partial or complete remission in eight of nine patients with MC.⁷⁰ A retrospective study found that the overall response rate to thiopurines (azathioprine 2 mg/kg/day) was 41% (19/46 patients); however, there were significant side effects that often led to withdrawal of therapy including hepatitis, pancreatitis, bone marrow suppression, and infection.^{39,71} A recent Mayo Clinic case series treated 49 patients with thiopurines for 4 months, and a complete response was seen in 43%, while a partial response was seen in 22%. Thirty-five percent of patients experienced adverse events leading to cessation of therapy.⁷²

The use of methotrexate in MC has had conflicting results. In a study of 19 patients with CC naïve to budesonide treated with methotrexate 5–25 mg orally weekly, the median dose 7.5–10 mg, a complete response was seen in 14 patients and a partial response was seen in two patients.⁷³ In another study of nine patients with CC treated with methotrexate 15–25 mg subcutaneously weekly, not a single patient improved and four patients experienced adverse events leading to cessation of therapy.⁷⁴ A Mayo Clinic case series examined 12 patients treated with methotrexate (mix of subcutaneous and oral dosing) 25 mg/week, of which 7 (58%) achieved complete response, 2 (17%) achieved partial response, and 3 (25%) had no response.⁷² Seventy-five percent of the patients in the Mayo Clinic cohort, however, were on concomitant budesonide therapy, limiting generalizability in the use of methotrexate as monotherapy. Given the conflicting reports on the efficacy of methotrexate in MC and the potential for significant adverse effects, further studies on methotrexate should be performed prior to recommending its use.

Calcineurin inhibitors have also been used in the treatment of MC. In one study, two patients were treated with calcineurin inhibitors (one with tacrolimus and one with

cyclosporine), with one patient (tacrolimus) achieving complete response without the use of budesonide.⁷² As this was the only article that included the use of calcineurin inhibitors, we do not recommend their use until more research is published.

Pentoxifylline

Pentoxifylline, a xanthine oxidase derivative with anti-tumor necrosis factor (TNF)-alpha properties, has been used in alcoholic hepatitis and intermittent claudication and may play a role in the treatment of MC according to a recent case report. Nine patients with MC either refractory to, intolerant of, or dependent on budesonide received pentoxifylline 400 mg three times a day for a median of 3 months. Complete response occurred in one patient (11%) and partial response occurred in three patients (33%); however, it should be noted that the one complete responder was intolerant to budesonide, leading the authors to surmise that this therapy could perhaps be used in patients intolerant to budesonide or those with a contraindication to its use.⁷²

Biologics

Overall, the use of anti-TNF-alpha drugs in MC can be considered for refractory cases as rescue therapy prior to surgical intervention.² As refractory MC is extremely uncommon, there is a lack of evidence on the use of anti-TNF-alpha therapy. What little data exist originates from case series involving adalimumab and infliximab. One such case series of ten patients (six with CC and four with LC) refractory to budesonide and immunomodulators prospectively evaluated adalimumab and infliximab at standard doses for inducing remission in inflammatory bowel disease.^{2,75} The study found that eight of ten patients achieved clinical and histologic remission as well as improvement in HRQOL.

The role of vedolizumab in the treatment of MC was highlighted in a case report of a 75-year-old woman with CC for 4 years who was refractory to budesonide and dependent on steroids. A standard induction dosing regimen was undertaken, and the patient experienced significant clinical improvement after two infusions, and histologic resolution was achieved at 3 months.⁷⁶ A recent case series of eleven cases of refractory MC (nine of eleven failed one immunosuppressant, ten of eleven failed at least one anti-TNF agent) treated with standard induction and maintenance dosing of vedolizumab (300 mg IV at weeks 0, 2, and 6, then every 8 weeks) observed clinical remission in five of eleven (45%) patients of whom 75% also had histologic remission.⁷⁷

Fecal transplant

Due to advances in the understanding of the gut microbiome, fecal transplant has become a new therapeutic avenue in disease such as *Clostridium difficile*. Its use in MC (specifically CC) has been examined in one case report of a patient refractory to budesonide who received three fecal transplants and achieved remission after the third for 11 months.⁷⁸ Interestingly, while the patient did ultimately relapse, she was then treated with budesonide with good clinical response, an effect that was unattainable prior to fecal transplant.

Surgery

The role of surgical management in MC is diminishing with considerable improvement and efficacy of available medical therapy. Nevertheless, it does have a role in severe and unresponsive MC.³⁹ Surgical therapy for MC includes ileostomy, subtotal colectomy, and ileal pouch anal anastomosis; however, data on this matter remain limited to individual reports.^{41,79,80}

Conclusion

MC is a disorder characterized by chronic diarrhea that is frequently encountered by gastroenterologists. The incidence and consequently awareness of this disease have been increasing. It is crucial to maintain a high index of suspicion in specific affected populations presenting with chronic diarrhea, particularly middle-aged women and the elderly, and to appropriately refer for colonoscopy with biopsy when needed. While there are two distinct histologic subtypes of MC, namely LC and CC, their clinical features and response to therapy do not differ significantly, and therefore, for the purposes of diagnosis and management, they can be treated as one entity of MC. While lifestyle modifications such as smoking cessation as well as a thorough medication review to remove potential triggers are beneficial, budesonide has been recommended by multiple international societies as the first-line therapy for the treatment of MC, replacing previous symptomatic-based therapies. Despite the high success rates with budesonide, there is a risk of relapse. Low-dose maintenance budesonide appears to be effective in treating relapsing MC, but further data are still needed. Alternative therapies have been described in MC, including methotrexate, mesalamine, antibiotics, and probiotics, but the limited available data thus far suggest these are not adequately effective. Cholestyramine may have a role in patients with concomitant bile acid malabsorption or in addition to mesalamine. The challenge arises with severe, budesonide-refractory disease. These patients may benefit from immunomodulators

or anti-TNF-alpha therapy though more data, particularly randomized placebo-controlled trials, are necessary. Surgery may be considered a last resort in severe disease unresponsive to other aforementioned therapies. Lastly, the burgeoning field exploring the gut microbiome is on the horizon for potential use in budesonide-refractory patients, via fecal transplant, to enhance response to standard therapy or as a means of therapy in itself.

Disclosure

The authors report no conflicts of interest in this work.

References

- O'Toole A. Optimal management of collagenous colitis: a review. *Clin Exp Gastroenterol*. 2016;9:31–39.
- Fernández-Bañares F, Casanova MJ, Arguedas Y, et al. Current concepts on microscopic colitis: evidence-based statements and recommendations of the Spanish microscopic colitis group. *Aliment Pharmacol Ther*. 2016;43(3):400–426.
- Nguyen GC, Smalley WE, Vege SS, Carrasco-Labra A; Clinical Guidelines Committee. American gastroenterological association Institute guideline on the medical management of microscopic colitis. *Gastroenterology*. 2016;150(1):242–246.
- Tong J, Zheng Q, Zheng Q, Lo R, Shen J, Ran Z. Incidence, prevalence, and temporal trends of microscopic colitis: a systematic review and meta-analysis. *Am J Gastroenterol*. 2015;110(2):265–276.
- Zabana Y, Ferrer C, Aceituno M, Salas A, Fernández-Bañares F. Advances for improved diagnosis of microscopic colitis in patients with chronic diarrhoea. *Gastroenterol Hepatol*. 2017;40(2):107–116.
- Bohr J, Tysk C, Eriksson S, Abrahamsson H, Järnerot G. Collagenous colitis: a retrospective study of clinical presentation and treatment in 163 patients. *Gut*. 1996;39(6):846–851.
- Macaigne G, Lahmek P, Locher C, et al. Microscopic colitis or functional bowel disease with diarrhea: a French prospective multicenter study. *Am J Gastroenterol*. 2014;109(9):1461–1470.
- Bonderup OK, Nielsen GL, Dall M, Pottegård A, Hallas J. Significant association between the use of different proton pump inhibitors and microscopic colitis: a nationwide Danish case-control study. *Aliment Pharmacol Ther*. 2018;48(6):618–625.
- Choi K, Abu-Sbeih H, Samdani R, et al. Can immune checkpoint inhibitors induce microscopic colitis or a brand new entity? *Inflamm Bowel Dis*. 2019;25(2):385–393.
- Lucendo AJ. Drug exposure and the risk of microscopic colitis: a critical update. *Drugs R D*. 2017;17(1):79–89.
- Vigren L, Sjöberg K, Benoni C, et al. Is smoking a risk factor for collagenous colitis? *Scand J Gastroenterol*. 2011;46(11):1334–1339.
- Koskela RM, Karttunen TJ, Niemelä SE, et al. Human leucocyte antigen and TNFalpha polymorphism association in microscopic colitis. *Eur J Gastroenterol Hepatol*. 2008;20(4):276–282.
- Green PH, Yang J, Cheng J, et al. An association between microscopic colitis and celiac disease. *Clin Gastroenterol Hepatol*. 2009;7(11):1210–1216.
- Sonnenberg A, Turner KO, Genta RM. Associations of microscopic colitis with other lymphocytic disorders of the gastrointestinal tract. *Clin Gastroenterol Hepatol*. 2018;16(11):1762–1767.
- Bürgel N, Bojarski C, Mankertz J, Zeitz M, Fromm M, Schulzke JD. Mechanisms of diarrhea in collagenous colitis. *Gastroenterology*. 2002;123(2):433–443.
- Bohr J, Järnerot G, Tysk C, Jones I, Eriksson S. Effect of fasting on diarrhoea in collagenous colitis. *Digestion*. 2002;65(1):30–34.

17. Ung KA, Gillberg R, Kilander A, Abrahamsson H. Role of bile acids and bile acid binding agents in patients with collagenous colitis. *Gut*. 2000;46(2):170–175.
18. Järnerot G, Bohr J, Tysk C, Eriksson S. Faecal stream diversion in patients with collagenous colitis. *Gut*. 1996;38(1):154–155.
19. Millien V, Rosen D, Hou J, Shah R. Proinflammatory sulfur-reducing bacteria are more abundant in colonic biopsies of patients with microscopic colitis compared to healthy controls. *Dig Dis Sci*. 2019;64(2):432–438.
20. Burke KE, Ananthkrishnan AN, Lochhead P, et al. Identification of menopausal and reproductive risk factors for microscopic colitis—results from the Nurses' Health study. *Gastroenterology*. 2018;155(6):1764–1775.
21. Gentile N, Yen EF. Prevalence, pathogenesis, diagnosis, and management of microscopic colitis. *Gut Liver*. 2018;12(3):227–235.
22. Nyhlin N, Wickbom A, Montgomery SM, Tysk C, Bohr J. Long-term prognosis of clinical symptoms and health-related quality of life in microscopic colitis: a case-control study. *Aliment Pharmacol Ther*. 2014;39(9):963–972.
23. Kane JS, Irvine AJ, Derwa Y, Ford AC. Fatigue and its associated factors in microscopic colitis. *Therap Adv Gastroenterol*. 2018;11(11):175628481879959.
24. Kamp EJ, Kane JS, Ford AC. Irritable bowel syndrome and microscopic colitis: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol*. 2016;14(5):659–668.
25. Roth B, Gustafsson RJ, Ohlsson B. Auto-antibodies and their association with clinical findings in women diagnosed with microscopic colitis. *PLoS One*. 2013;8(6):e66088.
26. Wildt S, Nordgaard-Lassen I, Bendtsen F, Rumessen JJ. Metabolic and inflammatory faecal markers in collagenous colitis. *Eur J Gastroenterol Hepatol*. 2007;19(7):567–574.
27. Fine KD, Ogunji F, George J, Niehaus MD, Guerrant RL. Utility of a rapid fecal latex agglutination test detecting the neutrophil protein, lactoferrin, for diagnosing inflammatory causes of chronic diarrhea. *Am J Gastroenterol*. 1998;93(8):1300–1305.
28. ASGE Standards of Practice Committee, Sharaf RN, Shergill AK, et al. Endoscopic mucosal tissue sampling. *Gastrointest Endosc*. 2013;78(2):216–224.
29. Moore M, Coleman HG, Allen PB, Loughrey MB. Microscopic colitis: a population-based case series over a 9-year period in Northern Ireland. *Colorectal Dis*. 2018;20(11):1020–1027.
30. Macaigne G, Lahmek P, Locher C, et al. Over 90% of cases of microscopic colitis can be diagnosed by performing a short colonoscopy. *Clin Res Hepatol Gastroenterol*. 2017;41(3):333–340.
31. Langner C, Aust D, Ensari A, et al. Histology of microscopic colitis—review with a practical approach for pathologists. *Histopathology*. 2015;66(5):613–626.
32. Guagnozzi D, Landolfi S, Vicario M. Towards a new paradigm of microscopic colitis: incomplete and variant forms. *World J Gastroenterol*. 2016;22(38):8459–8471.
33. Fernández-Bañares F, Zabana Y, Aceituno M, Ruiz L, Salas A, Esteve M. Prevalence and natural history of microscopic colitis: a population-based study with long-term clinical follow-up in Terrassa, Spain. *J Crohns Colitis*. 2016;10(7):805–811.
34. Tontini GE, Pastorelli L, Spina L, et al. Microscopic colitis and colorectal neoplastic lesion rate in chronic nonbloody diarrhea: a prospective, multicenter study. *Inflamm Bowel Dis*. 2014;20(5):882–891.
35. Hjortswang H, Tysk C, Bohr J, et al. Defining clinical criteria for clinical remission and disease activity in collagenous colitis. *Inflamm Bowel Dis*. 2009;15(12):1875–1881.
36. Clara AP, Magnago FD, Ferreira JN, Grillo TG. Microscopic colitis: a literature review. *Rev Assoc Med Bras*. 2016;62(9):895–900.
37. Münch A, Aust D, Bohr J, et al. Microscopic colitis: current status, present and future challenges. *J Crohns Colitis*. 2012;6(9):932–945.
38. Cotter TG, Binder M, Loftus EV, et al. Development of a Microscopic Colitis Disease Activity Index: a prospective cohort study. *Gut*. 2018;67(3):441–446.
39. Bohr J, Wickbom A, Hegedus A, Nyhlin N, Hultgren Hornquist E, Tysk C. Diagnosis and management of microscopic colitis: current perspectives. *Clin Exp Gastroenterol*. 2014;8:273–284.
40. Ingle SB, Adgaonkar BD, Ingle CR, Hinge C. Microscopic colitis: common cause of unexplained nonbloody diarrhea. *World J Gastrointest Pathophysiol*. 2014;5(1):48–53.
41. Cotter TG, Pardi DS. Current approach to the evaluation and management of microscopic colitis. *Curr Gastroenterol Rep*. 2017;19(2):8.
42. Münch A, Langner C. Microscopic colitis: clinical and pathologic perspectives. *Clin Gastroenterol Hepatol*. 2015;13(2):228–236.
43. McKeage K, Goa KL. Budesonide (Entocort EC capsules): a review of its therapeutic use in the management of active Crohn's disease in adults. *Drugs*. 2002;62(15):2263–2282.
44. Miehke S, Madisch A, Kupcinkas L, et al. Budesonide is more effective than mesalamine or placebo in short-term treatment of collagenous colitis. *Gastroenterology*. 2014;146(5):1222–1230.
45. Baert F, Schmit A, D'Haens G, et al. Budesonide in collagenous colitis: a double-blind placebo-controlled trial with histologic follow-up. *Gastroenterology*. 2002;122(1):20–25.
46. Bonderup OK, Hansen JB, Birket-Smith L, Vestergaard V, Teglbjaerg PS, Fallingborg J. Budesonide treatment of collagenous colitis: a randomised, double blind, placebo controlled trial with morphometric analysis. *Gut*. 2003;52(2):248–251.
47. Miehke S, Heymer P, Bethke B, et al. Budesonide treatment for collagenous colitis: a randomized, double-blind, placebo-controlled, multicenter trial. *Gastroenterology*. 2002;123(4):978–984.
48. Miehke S, Madisch A, Karimi D, et al. Budesonide is effective in treating lymphocytic colitis: a randomized double-blind placebo-controlled study. *Gastroenterology*. 2009;136(7):2092–2100.
49. Pardi DS, Loftus EV, Tremaine WJ, Sandborn WJ. T1193 a randomized, double-blind, placebo-controlled trial of budesonide for the treatment of active lymphocytic colitis. *Gastroenterology*. 2009;136(5):A-519–A-520.
50. Chande N, Al Yatama N, Bhanji T, et al. Interventions for treating lymphocytic colitis. *Cochrane Database Syst Rev*. 2017;7:CD006096.
51. Münch A, Bohr J, Miehke S, et al; BUC-63 investigators. Low-dose budesonide for maintenance of clinical remission in collagenous colitis: a randomised, placebo-controlled, 12-month trial. *Gut*. 2016;65(1):47–56.
52. Miehke S, Aust D, Mihaly E, et al. Efficacy and safety of budesonide, vs mesalazine or placebo, as induction therapy for lymphocytic colitis. *Gastroenterology*. 2018;155(6):1795–1804.
53. Boland K, Nguyen GC. Microscopic colitis: a review of collagenous and lymphocytic colitis. *Gastroenterol Hepatol (NY)*. 2017;13(11):671–677.
54. Fernández-Bañares F, Piqueras M, Guagnozzi D, et al. Collagenous colitis: requirement for high-dose budesonide as maintenance treatment. *Dig Liver Dis*. 2017;49(9):973–977.
55. DeCorte T, Janssens E, Thorrez K, et al. Beclomethasone dipropionate is effective for microscopic colitis: results of an open-label multicentre study (COLCO). European Crohn's and Colitis Organisation Digital Oral Presentation Session 4: Practicalities of IBD Patient Care; 2018; Vienna, Austria.
56. Munck LK, Kjeldsen J, Philipsen E, Fischer Hansen B. Incomplete remission with short-term prednisolone treatment in collagenous colitis: a randomized study. *Scand J Gastroenterol*. 2003;38(6):606–610.
57. Gentile NM, Abdalla AA, Khanna S, et al. Outcomes of patients with microscopic colitis treated with corticosteroids: a population-based study. *Am J Gastroenterol*. 2013;108(2):256–259.
58. Munck L, Kielsen J, Fischer Hansen B. Incomplete remission with short-term prednisolone treatment in collagenous colitis: a randomized study. *Scand Gastroenterol*. 2003;38(6):606–610.
59. Fine K, Lee E, Lafon G. Randomized double-blind, placebo-controlled trial of bismuth subsalicylate for microscopic colitis. *Gastroenterology*. 1999;116:A880.
60. Gentile NM, Khanna S, Loftus EV, Tremaine WJ, Kammer PP, Pardi DS. S1353 outcomes of patients with microscopic colitis treated with bismuth subsalicylate. *Gastroenterology*. 2015;148(4):S-483.

61. Amaro R, Poniecka A, Rogers AI. Collagenous colitis treated successfully with bismuth subsalicylate. *Dig Dis Sci*. 2000;45(7):1447–1450.
62. Tillman LA, Drake FM, Dixon JS, Wood JR. Review article: safety of bismuth in the treatment of gastrointestinal diseases. *Aliment Pharmacol Ther*. 1996;10(4):459–467.
63. Calabrese C, Fabbri A, Areni A, et al. Mesalazine with or without cholestyramine in the treatment of microscopic colitis: randomized controlled trial. *J Gastroenterol Hepatol*. 2007;22(6):809–814.
64. Pardi DS, Ramnath VR, Loftus EV, Tremaine WJ, Sandborn WJ. Lymphocytic colitis: clinical features, treatment, and outcomes. *Am J Gastroenterol*. 2002;97(11):2829–2833.
65. Madisch A, Miehlke S, Eichele O, et al. *Boswellia serrata* extract for the treatment of collagenous colitis. A double-blind, randomized, placebo-controlled, multicenter trial. *Int J Colorectal Dis*. 2007;22(12):1445–1451.
66. Wildt S, Munck LK, Vinter-Jensen L, et al. Probiotic treatment of collagenous colitis: a randomized, double-blind, placebo-controlled trial with *Lactobacillus acidophilus* and *Bifidobacterium animalis* subsp. *lactis*. *Inflamm Bowel Dis*. 2006;12(5):395–401.
67. Tromm A, Niewerth U, Khoury M, et al. The probiotic *E. coli* strain Nissle 1917 for the treatment of collagenous colitis: first results of an open-label trial. *Z Gastroenterol*. 2004;42(5):365–369.
68. Rohatgi S, Ahuja V, Makharia GK, et al. VSL#3 induces and maintains short-term clinical response in patients with active microscopic colitis: a two-phase randomised clinical trial. *BMJ Open Gastroenterol*. 2015;2(1):e000018.
69. Olesen M, Eriksson S, Bohr J, Järnerot G, Tysk C. Lymphocytic colitis: a retrospective clinical study of 199 Swedish patients. *Gut*. 2004;53(4):536–541.
70. Pardi DS, Loftus EV, Tremaine WJ, Sandborn WJ. Treatment of refractory microscopic colitis with azathioprine and 6-mercaptopurine. *Gastroenterology*. 2001;120(6):1483–1484.
71. Münch A, Fernandez-Banares F, Munck LK. Azathioprine and mercaptopurine in the management of patients with chronic, active microscopic colitis. *Aliment Pharmacol Ther*. 2013;37(8):795–798.
72. Cotter TG, Kamboj AK, Hicks SB, Tremaine WJ, Loftus EV, Pardi DS. Immune modulator therapy for microscopic colitis in a case series of 73 patients. *Aliment Pharmacol Ther*. 2017;46(2):169–174.
73. Riddell J, Hillman L, Chiragakis L, Clarke A. Collagenous colitis: oral low-dose methotrexate for patients with difficult symptoms: long-term outcomes. *J Gastroenterol Hepatol*. 2007;22(10):1589–1593.
74. Münch A, Bohr J, Vigren L, Tysk C, Ström M. Lack of effect of methotrexate in budesonide-refractory collagenous colitis. *Clin Exp Gastroenterol*. 2013;6:149–152.
75. Esteve M, Mahadevan U, Sainz E, Rodriguez E, Salas A, Fernández-Bañares F. Efficacy of anti-TNF therapies in refractory severe microscopic colitis. *J Crohns Colitis*. 2011;5(6):612–618.
76. Cushing KC, Mino-Kenudson M, Garber J, Lochhead P, Khalili H. Vedolizumab as a novel treatment for refractory collagenous colitis: a case report. *Am J Gastroenterol*. 2018;113(4):632–633.
77. Rivière P, Münch A, Michetti P, et al. Vedolizumab in refractory microscopic colitis: an international case series. *J Crohns Colitis*. Epub 2018 Oct 17.
78. Günaltay S, Rademacher L, Hultgren Hörnquist E, Bohr J. Clinical and immunologic effects of faecal microbiota transplantation in a patient with collagenous colitis. *World J Gastroenterol*. 2017;23(7):1319–1324.
79. Varghese L, Galandiuk S, Tremaine WJ, Burgart LJ. Lymphocytic colitis treated with proctocolectomy and ileal J-pouch-anal anastomosis: report of a case. *Dis Colon Rectum*. 2002;45(1):123–126.
80. Yusuf TE, Soemijarsih M, Arpaia A, Goldberg SL, Sottile VM. Chronic microscopic enterocolitis with severe hypokalemia responding to subtotal colectomy. *J Clin Gastroenterol*. 1999;29(3):284–288.

Clinical and Experimental Gastroenterology

Publish your work in this journal

Clinical and Experimental Gastroenterology is an international, peer-reviewed, open access, online journal publishing original research, reports, editorials, reviews and commentaries on all aspects of gastroenterology in the clinic and laboratory. This journal is included on PubMed. The manuscript management system is completely online

Submit your manuscript here: <https://www.dovepress.com/clinical-and-experimental-gastroenterology-journal>

Dovepress

and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.